BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh MV, Cicha MZ, Meyerholz DK, Chapleau MW, Abboud FM. Dual Activation of TRIF and MyD88 Adaptor Proteins by Angiotensin II Evokes Opposing Effects on Pressure, Cardiac Hypertrophy, and Inflammatory Gene Expression. Hypertension 2015;66:647-56. [PMID: 26195481 DOI: 10.1161/HYPERTENSIONAHA.115.06011] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Wild J, Wenzel P. Myeloid cells, tissue homeostasis, and anatomical barriers as innate immune effectors in arterial hypertension. J Mol Med (Berl) 2021;99:315-26. [PMID: 33443617 DOI: 10.1007/s00109-020-02019-1] [Reference Citation Analysis]
2 Zhang RM, McNerney KP, Riek AE, Bernal-Mizrachi C. Immunity and Hypertension. Acta Physiol (Oxf) 2021;231:e13487. [PMID: 32359222 DOI: 10.1111/apha.13487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
3 Dick SA, Epelman S. Chronic Heart Failure and Inflammation: What Do We Really Know? Circ Res 2016;119:159-76. [DOI: 10.1161/circresaha.116.308030] [Cited by in Crossref: 236] [Cited by in F6Publishing: 137] [Article Influence: 39.3] [Reference Citation Analysis]
4 Singh MV. Toll-Like Receptors, Hypertension, and an Antimalarial Drug. Am J Hypertens 2017;30:118-9. [PMID: 27702749 DOI: 10.1093/ajh/hpw128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Crowley SD, Jeffs AD. Targeting cytokine signaling in salt-sensitive hypertension. Am J Physiol Renal Physiol 2016;311:F1153-8. [PMID: 27558557 DOI: 10.1152/ajprenal.00273.2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liu L, Lu Y, Bi X, Xu M, Yu X, Xue R, He X, Zang W. Choline ameliorates cardiovascular damage by improving vagal activity and inhibiting the inflammatory response in spontaneously hypertensive rats. Sci Rep 2017;7:42553. [PMID: 28225018 DOI: 10.1038/srep42553] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
7 Tao L, Jia L, Li Y, Song C, Chen Z. Recent advances of adapter proteins in the regulation of heart diseases. Heart Fail Rev 2017;22:99-107. [PMID: 27623843 DOI: 10.1007/s10741-016-9582-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Nunes KP, de Oliveira AA, Lima VV, Webb RC. Toll-Like Receptor 4 and Blood Pressure: Lessons From Animal Studies. Front Physiol 2019;10:655. [PMID: 31191352 DOI: 10.3389/fphys.2019.00655] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
9 Singh MV, Cicha MZ, Nunez S, Meyerholz DK, Chapleau MW, Abboud FM. Angiotensin II-induced hypertension and cardiac hypertrophy are differentially mediated by TLR3- and TLR4-dependent pathways. Am J Physiol Heart Circ Physiol 2019;316:H1027-38. [PMID: 30793936 DOI: 10.1152/ajpheart.00697.2018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
10 Majumder S, Pushpakumar S, Juin SK, Jala VR, Sen U. Toll-like receptor 4 mutation protects the kidney from Ang-II-induced hypertensive injury. Pharmacol Res 2021;175:106030. [PMID: 34896544 DOI: 10.1016/j.phrs.2021.106030] [Reference Citation Analysis]
11 Xiao Z, Kong B, Yang H, Dai C, Fang J, Qin T, Huang H. Key Player in Cardiac Hypertrophy, Emphasizing the Role of Toll-Like Receptor 4. Front Cardiovasc Med 2020;7:579036. [PMID: 33324685 DOI: 10.3389/fcvm.2020.579036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Guzik TJ, Touyz RM. Oxidative Stress, Inflammation, and Vascular Aging in Hypertension. Hypertension 2017;70:660-7. [PMID: 28784646 DOI: 10.1161/HYPERTENSIONAHA.117.07802] [Cited by in Crossref: 202] [Cited by in F6Publishing: 110] [Article Influence: 40.4] [Reference Citation Analysis]
13 Saikh KU. MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity. Immunol Res 2021;69:117-28. [PMID: 33834387 DOI: 10.1007/s12026-021-09188-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
14 Marvar PJ, Hendy EB, Cruise TD, Walas D, DeCicco D, Vadigepalli R, Schwaber JS, Waki H, Murphy D, Paton JF. Systemic leukotriene B4 receptor antagonism lowers arterial blood pressure and improves autonomic function in the spontaneously hypertensive rat. J Physiol 2016;594:5975-89. [PMID: 27230966 DOI: 10.1113/JP272065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
15 Singh MV, Cicha MZ, Kumar S, Meyerholz DK, Irani K, Chapleau MW, Abboud FM. Abnormal CD161+ immune cells and retinoic acid receptor-related orphan receptor γt-mediate enhanced IL-17F expression in the setting of genetic hypertension. J Allergy Clin Immunol 2017;140:809-821.e3. [PMID: 28093217 DOI: 10.1016/j.jaci.2016.11.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
16 Antoniak S, Cardenas JC, Buczek LJ, Church FC, Mackman N, Pawlinski R. Protease-Activated Receptor 1 Contributes to Angiotensin II-Induced Cardiovascular Remodeling and Inflammation. Cardiology 2017;136:258-68. [PMID: 27880950 DOI: 10.1159/000452269] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
17 Lin S, Dai S, Lin J, Liang X, Wang W, Huang W, Ye B, Hong X, Tomlinson B. Oridonin Relieves Angiotensin II-Induced Cardiac Remodeling via Inhibiting GSDMD-Mediated Inflammation. Cardiovascular Therapeutics 2022;2022:1-17. [DOI: 10.1155/2022/3167959] [Reference Citation Analysis]
18 McCarthy CG, Wenceslau CF, Goulopoulou S, Baban B, Matsumoto T, Webb RC. Chloroquine Suppresses the Development of Hypertension in Spontaneously Hypertensive Rats. Am J Hypertens 2017;30:173-81. [PMID: 27623761 DOI: 10.1093/ajh/hpw113] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
19 Mian MOR, He Y, Bertagnolli M, Mai-Vo TA, Fernandes RO, Boudreau F, Cloutier A, Luu TM, Nuyt AM. TLR (Toll-Like Receptor) 4 Antagonism Prevents Left Ventricular Hypertrophy and Dysfunction Caused by Neonatal Hyperoxia Exposure in Rats. Hypertension 2019;74:843-53. [PMID: 31476902 DOI: 10.1161/HYPERTENSIONAHA.119.13022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
20 Abboud FM. Four evolving concepts in molecular and clinical autonomic research. Clin Auton Res 2021;31:467-71. [PMID: 34191210 DOI: 10.1007/s10286-021-00816-3] [Reference Citation Analysis]